BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024

VANCOUVER, BC, April 5, 2024 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative metallotherapeutics, has announced that Dr. Do-Youn Oh’s group at Seoul National University College of Medicine, Seoul, South Korea, will be…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.